INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Spaide, 2006, Perspectives article. Rationale for combination therapies for choroidal neovascularization., Am J Ophthalmol, 141, 149, 10.1016/j.ajo.2005.07.025

1982, Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial., Arch Ophthalmol, 100, 912, 10.1001/archopht.1982.01030030920003

1990, Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration., Arch Ophthalmol, 108, 825, 10.1001/archopht.1990.01070080067037

Bressler, 2001, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2., Arch Ophthalmol, 119, 198

2001, Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2., Am J Ophthalmol, 131, 541, 10.1016/S0002-9394(01)00967-9

Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration., N Engl J Med, 351, 2805, 10.1056/NEJMoa042760

Spaide, 2006, New treatments for AMD., Ophthalmology, 113, 160, 10.1016/j.ophtha.2005.10.023

Mordenti, 1999, Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration., Toxicol Pathol, 27, 536, 10.1177/019262339902700507

Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer., Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381

Michels, 2005, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label study., Ophthalmology, 112, 1035, 10.1016/j.ophtha.2005.02.007

Rosenfeld, 2005, Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration., Ophthalmic Surg Lasers Imaging, 36, 270

Aiello, 2004, Evolving guidelines for intravitreous injections., Retina, 24, 13, 10.1097/00006982-200410001-00002

Jackson, 2003, Human retinal molecular weight exclusion limit and estimate of species variation., Invest Ophthalmol Vis Sci, 44, 2141, 10.1167/iovs.02-1027

Ravetch, 2001, IgG Fc receptors., Annu Rev Immunol, 19, 275, 10.1146/annurev.immunol.19.1.275

Ma, 2005, In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy., Cancer Res, 65, 5365, 10.1158/0008-5472.CAN-04-3156

D'Amico, 2003, Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes., Ophthalmology, 110, 2372, 10.1016/j.ophtha.2003.08.020

Slakter, 2006, Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration., Ophthalmology, 113, 3, 10.1016/j.ophtha.2005.10.019